Chapter 026

Procoagulant, Anticoagulant, and Thrombolytic Drugs

Barton S. Johnson

GENERAL REFERENCES

  1. AHFS drug information 2015, Bethesda, MD, 2015, American Society of Health-System Pharmacists.
  2. Grines CL, Bonow RO, Casey Jr DE: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians, J Am Dent Assoc 138:652–655, 2007. PUBMED Abstract
  3. Hillman RS, Ault KA, Leporrier M, Rinder H: Hematology in Clinical Practice, ed 5, New York, 2010, McGraw-Hill.
  4. Kaushansky K, Lichtman MA, Beutler E, et al.: Williams Hematology, ed 8, New York, 2010, McGraw-Hill.
  5. Papadakis MA, McPhee SJ, Rabow MW, editors: Current Medical Diagnosis and Treatment 2015, Stamford, CT, 2015, Lange Medical Books/ McGraw-Hill.
  6. Weitz J: Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs. In Brunton LL, Chabner B, Knollman B, editors: Goodman & Gillman’s the Pharmacological Basis of Therapeutics, ed 12, New York, 2010, McGraw-Hill.